This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

In light of recent revelations surrounding a new intranasal COVID-19 vaccine candidate, there is growing concern that the American public is once again being led into potentially dangerous territory ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

The annual football game at Sportsman's Park in the 1930s drew big crowds ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

The mass layoffs of federal employees have been unprecedented, devastating, and chaotic but it is the cuts to HHS that are ...

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...